American pharmaceutical company Abbott Laboratories has launched dissolvable stents, known as Bioresorbable Vascular Scaffold, in India.
The stent was cleared for use by the Drugs Controller General of India (DCGI) for clearing blockages in patients with clogged arteries, such as in coronary artery disease. The stent has already been launched in a number of countries, including in Europe, but is yet to be approved by the US Food and Drug Administration.
The stent had been used by doctors at Fortis Escorts Heart Institute as part of the trial to test its effectiveness and the chairman of Fortis Healthcare, Dr Ashok Seth said that it provided doctors with increased treatment options.
"With BVS, we can offer our patients a significant advancement in treating coronary artery diseases. The structure starts to resorb within one year, allowing the vessel the potential to flex, pulsate and dilate in response to normal activities such as exercise. This technology may allow blood vessels to return to a more natural state and expand long-term diagnostic and treatment options", he said.